The venture capital arm of a Taiwanese financial conglomerate with about NT$ 2 trillion (USD 31 billion) AUM is looking to invest in the biotechnology, and medical/healthcare and IT sectors. Typical equity allocations range from US$1-3 million and can be up to US$5 million. Historically the firm mainly invested in early-late stage companies in Taiwan, however currently the firm is actively seeking new investment opportunities from North America and Europe.
Within healthcare, the firm is interested in all sectors of medical technology, including both consumer and non-consumer products. The firm is agnostic to indications. The firm is less interested in therapeutics, but it would consider drug reformulation. The firm looks for products that are ready for commercialization or at the commercial stage and seeking growth/expansion capital.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com





Leave a comment